Jiri Neuzil

List of Publications by Year
in descending order

210 papers	12,898 citations	15466 65 h-index	30010 103 g-index
222 all docs	222 docs citations	222 times ranked	13276 citing authors

#	Article	IF	Citations
1	Germline <i>SUCLG2</i> Variants in Patients With Pheochromocytoma and Paraganglioma. Journal of the National Cancer Institute, 2022, 114, 130-138.	3.0	21
2	Mitochondrial respiration supports autophagy to provide stress resistance during quiescence. Autophagy, 2022, 18, 2409-2426.	4.3	13
3	Simultaneous targeting of mitochondrial metabolism and immune checkpoints as a new strategy for renal cancer therapy. Clinical and Translational Medicine, 2022, 12, e645.	1.7	10
4	Mitochondrially targeted tamoxifen alleviates markers of obesity and type 2 diabetes mellitus in mice. Nature Communications, 2022, 13, 1866.	5.8	8
5	Oxidative stress and Rho GTPases in the biogenesis of tunnelling nanotubes: implications in disease and therapy. Cellular and Molecular Life Sciences, 2022, 79, 1.	2.4	10
6	Optimized expression of alternative oxidase. Gene Therapy, 2022, 29, 653-654.	2.3	1
7	Alpha-Synuclein Aggregates Associated with Mitochondria in Tunnelling Nanotubes. Neurotoxicity Research, 2021, 39, 429-443.	1.3	21
8	Platelets Facilitate the Wound-Healing Capability of Mesenchymal Stem Cells by Mitochondrial Transfer and Metabolic Reprogramming. Cell Metabolism, 2021, 33, 283-299.e9.	7.2	102
9	Targeting Mitochondrial Iron Metabolism Suppresses Tumor Growth and Metastasis by Inducing Mitochondrial Dysfunction and Mitophagy. Cancer Research, 2021, 81, 2289-2303.	0.4	51
10	Mitochondrial Function, Fatty Acid Metabolism, and Body Composition in the Hyperbilirubinemic Gunn Rat. Frontiers in Pharmacology, 2021, 12, 586715.	1.6	3
11	Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. Frontiers in Endocrinology, 2021, 12, 589451.	1.5	25
12	SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy. Oncogene, 2021, 40, 2539-2552.	2.6	18
13	Novel Germline <i>SUCLG2</i> Mutations in Patients With Pheochromocytoma and Paraganglioma. Journal of the Endocrine Society, 2021, 5, A168-A169.	0.1	0
14	Miro proteins connect mitochondrial function and intercellular transport. Critical Reviews in Biochemistry and Molecular Biology, 2021, 56, 1-25.	2.3	11
15	Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma. Cancers, 2021, 13, 3769.	1.7	3
16	Mechanisms of resistance to mitochondria-targeted therapy in pancreatic cancer. Oncotarget, 2021, 12, 1627-1628.	0.8	1
17	Quantitative analysis of neuronal mitochondrial movement reveals patterns resulting from neurotoxicity of rotenone and 6â€hydroxydopamine. FASEB Journal, 2021, 35, e22024.	0.2	2
18	A simple indirect colorimetric assay for measuring mitochondrial energy metabolism based on uncoupling sensitivity. Biochemistry and Biophysics Reports, 2020, 24, 100858.	0.7	0

#	Article	IF	Citations
19	Mitocans Revisited: Mitochondrial Targeting as Efficient Anti-Cancer Therapy. International Journal of Molecular Sciences, 2020, 21, 7941.	1.8	73
20	Mitochondrial DNA Affects the Expression of Nuclear Genes Involved in Immune and Stress Responses in a Breast Cancer Model. Frontiers in Physiology, 2020, 11, 543962.	1.3	6
21	Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics, 2020, 10, 5259-5275.	4.6	39
22	Therapeutic Targeting of<i>SDHB</i>-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. Clinical Cancer Research, 2020, 26, 3868-3880.	3.2	29
23	Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165759.	1.8	73
24	Mitochondria-adaptor TRAK1 promotes kinesin-1 driven transport in crowded environments. Nature Communications, 2020, 11, 3123.	5.8	60
25	Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors. Cell Death and Disease, 2020, 11, 110.	2.7	27
26	Mitochondrial complex II and reactive oxygen species in disease and therapy. Redox Report, 2020, 25, 26-32.	1.4	85
27	Mechanism of miR-222 and miR-126 regulation and its role in asbestos-induced malignancy. International Journal of Biochemistry and Cell Biology, 2020, 121, 105700.	1.2	11
28	Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2. Cell Death and Differentiation, 2019, 26, 276-290.	5.0	69
29	Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication. Cancer Letters, 2019, 463, 27-36.	3.2	42
30	Intracellular and Intercellular Mitochondrial Dynamics in Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 930.	1.4	55
31	Targeting mitochondria as an anticancer strategy. Cancer Communications, 2019, 39, 1-3.	3.7	77
32	Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. Frontiers in Oncology, 2019, 9, 53.	1.3	39
33	Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy. Frontiers in Oncology, 2019, 9, 1293.	1.3	36
34	Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. Cell Metabolism, 2019, 29, 399-416.e10.	7.2	190
35	Mitochondria-driven elimination of cancer and senescent cells. Biological Chemistry, 2019, 400, 141-148.	1.2	13
36	Four-miRNA Signature to Identify Asbestos-Related Lung Malignancies. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 119-126.	1.1	27

#	Article	IF	Citations
37	Mitochondria break through cellular boundaries. Aging, 2019, 11, 4308-4309.	1.4	1
38	Mitochondrial Genome Transfer to Tumor Cells Breaks The Rules and Establishes a New Precedent in Cancer Biology. Molecular and Cellular Oncology, 2018, 5, e1023929.	0.3	20
39	Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity. IScience, 2018, 3, 192-207.	1.9	40
40	TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor. Biochimica Et Biophysica Acta - Molecular Cell Research, 2018, 1865, 522-531.	1.9	32
41	Mitocans: Mitochondrially Targeted Anti-cancer Drugs. , 2018, , 613-635.		6
42	MiR-126 in intestinal-type sinonasal adenocarcinomas: exosomal transfer of MiR-126 promotes anti-tumour responses. BMC Cancer, 2018, 18, 896.	1.1	17
43	Metformin directly targets the H3K27me3 demethylase KDM6A/UTX. Aging Cell, 2018, 17, e12772.	3.0	58
44	Alternative assembly of respiratory complex II connects energy stress to metabolic checkpoints. Nature Communications, 2018, 9, 2221.	5.8	44
45	Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy. Lung Cancer, 2017, 107, 65-72.	0.9	36
46	Selective Disruption of Respiratory Supercomplexes as a New Strategy to Suppress Her2^{high} Breast Cancer. Antioxidants and Redox Signaling, 2017, 26, 84-103.	2.5	93
47	Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy. Experimental and Molecular Medicine, 2017, 49, e285-e285.	3.2	169
48	Mitochondrial Complex II: At the Crossroads. Trends in Biochemical Sciences, 2017, 42, 312-325.	3.7	192
49	The mobility of mitochondria: Intercellular trafficking in health and disease. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 15-20.	0.9	27
50	Antioxidant defense in quiescent cells determines selectivity of electron transport chain inhibition-induced cell death. Free Radical Biology and Medicine, 2017, 112, 253-266.	1.3	20
51	Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression. Scientific Reports, 2017, 7, 15277.	1.6	121
52	Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism. Oncotarget, 2017, 8, 6376-6398.	0.8	72
53	Horizontal transfer of whole mitochondria restores tumorigenic potential in mitochondrial DNA-deficient cancer cells. ELife, 2017, 6, .	2.8	205
54	MicroRNA in Metabolic Re-Programming and Their Role in Tumorigenesis. International Journal of Molecular Sciences, 2016, 17, 754.	1.8	44

#	Article	IF	Citations
55	Horizontal transfer of mitochondria between mammalian cells: beyond co-culture approaches. Current Opinion in Genetics and Development, 2016, 38, 75-82.	1.5	68
56	The role of Her2 and other oncogenes of the PI3K/AKT pathway in mitochondria. Biological Chemistry, 2016, 397, 607-615.	1.2	26
57	The Assembly Factor SDHAF2 Is Dispensable for Flavination of the Catalytic Subunit of Mitochondrial Complex II in Breast Cancer Cells. Journal of Biological Chemistry, 2016, 291, 21414-21420.	1.6	17
58	Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer. Molecular Cancer Therapeutics, 2016, 15, 2875-2886.	1.9	65
59	Mitochondria: An intriguing target for killing tumour-initiating cells. Mitochondrion, 2016, 26, 86-93.	1.6	35
60	Transcriptional profiling of dividing tumor cells detects intratumor heterogeneity linked to cell proliferation in a brain tumor model. Molecular Oncology, 2016, 10, 126-137.	2.1	17
61	Isolating dividing neural and brain tumour cells for gene expression profiling. Journal of Neuroscience Methods, 2016, 257, 121-133.	1.3	4
62	MicroRNA-126 induces autophagy by altering cell metabolism in malignant mesothelioma. Oncotarget, 2016, 7, 36338-36352.	0.8	41
63	Characterisation of Mesothelioma-Initiating Cells and Their Susceptibility to Anti-Cancer Agents. PLoS ONE, 2015, 10, e0119549.	1.1	23
64	Mitochondrial Genome Acquisition Restores Respiratory Function and Tumorigenic Potential of Cancer Cells without Mitochondrial DNA. Cell Metabolism, 2015, 21, 81-94.	7.2	582
65	Evaluation of Respiration of Mitochondria in Cancer Cells Exposed to Mitochondria-Targeted Agents. Methods in Molecular Biology, 2015, 1265, 181-194.	0.4	2
66	Mitochondrially Targeted Vitamin E Succinate Modulates Expression of Mitochondrial DNA Transcripts and Mitochondrial Biogenesis. Antioxidants and Redox Signaling, 2015, 22, 883-900.	2.5	39
67	Mitochondrial DNA in Tumor Initiation, Progression, and Metastasis: Role of Horizontal mtDNA Transfer. Cancer Research, 2015, 75, 3203-3208.	0.4	56
68	Selenium supplementation induces mitochondrial biogenesis in trophoblasts. Placenta, 2015, 36, 863-869.	0.7	41
69	Liposomal delivery systems for anti-cancer analogues of vitamin E. Journal of Controlled Release, 2015, 207, 59-69.	4.8	57
70	Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer, 2015, 90, 457-464.	0.9	51
71	Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner. BMC Cancer, 2015, 15, 401.	1.1	63
72	The Effect of Mitochondrially Targeted Anticancer Agents on Mitochondrial (Super)Complexes. Methods in Molecular Biology, 2015, 1265, 195-208.	0.4	10

#	Article	IF	Citations
73	Powerhouse down: Complex II dissociation in the respiratory chain. Mitochondrion, 2014, 19, 20-28.	1.6	37
74	Structural Re-arrangement and Peroxidase Activation of Cytochrome c by Anionic Analogues of Vitamin E, Tocopherol Succinate and Tocopherol Phosphate. Journal of Biological Chemistry, 2014, 289, 32488-32498.	1.6	15
75	MicroRNA-126 Suppresses Mesothelioma Malignancy by Targeting IRS1 and Interfering with the Mitochondrial Function. Antioxidants and Redox Signaling, 2014, 21, 2109-2125.	2.5	85
76	Mitochondrial targeting of Î±-tocopheryl succinate enhances its anti-mesothelioma efficacy. Redox Report, 2014, 19, 16-25.	1.4	29
77	Regulation of Mitochondrial Function by MicroRNA. , 2014, , 59-80.		0
78	Mitochondrial Complex II in Cancer. , 2014, , 81-104.		0
79	MicroRNAs as regulators of mitochondrial function: Role in cancer suppression. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 1441-1453.	1.1	61
80	Mitochondria in Cancer. Progress in Molecular Biology and Translational Science, 2014, 127, 211-227.	0.9	31
81	Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans. Free Radical Biology and Medicine, 2014, 67, 41-50.	1.3	27
82	MicroRNA regulation of cancer metabolism: role in tumour suppression. Mitochondrion, 2014, 19, 29-38.	1.6	32
83	Vitamin E Analogues as Prototypic Mitochondria-Targeting Anti-cancer Agents. , 2014, , 151-181.		2
84	Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to Î±-tocopheryl succinate. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 286-299.	2.2	32
85	Reactive oxygen species are generated by the respiratory complexÂ<scp>II</scp> â€“ evidence for lack of contribution of the reverse electron flow in complexÂ<scp>I</scp>. FEBS Journal, 2013, 280, 927-938.	2.2	60
86	Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion, 2013, 13, 199-208.	1.6	199
87	Mitochondrial complex II, a novel target for anti-cancer agents. Biochimica Et Biophysica Acta - Bioenergetics, 2013, 1827, 552-564.	0.5	87
88	Editorial (Hot Topic: The Bioenergetics of Cancer, the Warburg Hypothesis and the Mitochondrial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.9	2
89	High Molecular Weight Forms of Mammalian Respiratory Chain Complex II. PLoS ONE, 2013, 8, e71869.	1.1	12
90	Targeting the Mitochondrial Electron Transport Chain Complexes for the Induction of Apoptosis and Cancer Treatment. Current Pharmaceutical Biotechnology, 2013, 14, 377-389.	0.9	30

#	Article	IF	Citations
91	K-Ras and mitochondria: Dangerous liaisons. Cell Research, 2012, 22, 285-287.	5.7	17
92	Mitocans, Mitochondria-Targeting Anticancer Drugs. Oxidative Stress and Disease, 2012, , 55-91.	0.3	1
93	Molecular mechanism for the selective impairment of cancer mitochondrial function by a mitochondrially targeted vitamin E analogue. Biochimica Et Biophysica Acta - Bioenergetics, 2012, 1817, 1597-1607.	0.5	32
94	Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clinical Biochemistry, 2012, 45, 575-581.	0.8	93
95	Alpha-Tocopheryl Succinate Inhibits Autophagic Survival of Prostate Cancer Cells Induced by Vitamin K3 and Ascorbate to Trigger Cell Death. PLoS ONE, 2012, 7, e52263.	1.1	33
96	Î±â€Tocopheryloxyacetic acid is superior to Î±â€tocopheryl succinate in suppressing HER2â€high breast carcinomas due to its higher stability. International Journal of Cancer, 2012, 131, 1052-1058.	2.3	22
97	Succinobucol induces apoptosis in vascular smooth muscle cells. Free Radical Biology and Medicine, 2012, 52, 871-879.	1.3	9
98	Hippo/Mst1 Stimulates Transcription of the Proapoptotic Mediator <i>NOXA</i> in a FoxO1-Dependent Manner. Cancer Research, 2011, 71, 946-954.	0.4	91
99	Anticancer Drugs Targeting the Mitochondrial Electron Transport Chain. Antioxidants and Redox Signaling, 2011, 15, 2951-2974.	2.5	79
100	The Potential Role of CD133 in Immune Surveillance and Apoptosis: A Mitochondrial Connection?. Antioxidants and Redox Signaling, 2011, 15, 2989-3002.	2.5	8
101	Drugs that Kill Cancer Stem-like Cells. , 2011, , .		2
102	Mitochondrial targeting of Î±-tocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm for effective cancer therapy. Free Radical Biology and Medicine, 2011, 50, 1546-1555.	1.3	100
103	Mitochondrially Targeted Î±-Tocopheryl Succinate Is Antiangiogenic: Potential Benefit Against Tumor Angiogenesis but Caution Against Wound Healing. Antioxidants and Redox Signaling, 2011, 15, 2923-2935.	2.5	48
104	Inhibitors of Succinate: Quinone Reductase/Complex II Regulate Production of Mitochondrial Reactive Oxygen Species and Protect Normal Cells from Ischemic Damage but Induce Specific Cancer Cell Death. Pharmaceutical Research, 2011, 28, 2695-2730.	1.7	108
105	Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis, 2011, 14, 293-307.	3.7	84
106	Affinity of vitamin E analogues for the ubiquinone complex II site correlates with their toxicity to cancer cells. Molecular Nutrition and Food Research, 2011, 55, 1543-1551.	1.5	9
107	Thrombomodulin Is Silenced in Malignant Mesothelioma by a Poly(ADP-ribose) Polymerase-1-mediated Epigenetic Mechanism. Journal of Biological Chemistry, 2011, 286, 19478-19488.	1.6	26
108	Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis. Mutagenesis, 2011, 26, 585-591.	1.0	16

#	Article	IF	Citations
109	Mitochondrial Targeting of Vitamin E Succinate Enhances Its Pro-apoptotic and Anti-cancer Activity via Mitochondrial Complex II. Journal of Biological Chemistry, 2011, 286, 3717-3728.	1.6	171
110	Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma. PLoS ONE, 2011, 6, e18232.	1.1	93
111	Î±-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 782-794.	2.2	51
112	Lyophilised liposomeâ€based formulations of Î±â€tocopheryl succinate: Preparation and physicoâ€chemical characterisation. Journal of Pharmaceutical Sciences, 2010, 99, 2434-2443.	1.6	24
113	Î±-Tocopheryl succinate promotes selective cell death induced by vitamin K3 in combination with ascorbate. British Journal of Cancer, 2010, 102, 1224-1234.	2.9	26
114	Mitochondrially targeted anti-cancer agents. Mitochondrion, 2010, 10, 670-681.	1.6	114
115	Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Molecular Aspects of Medicine, 2010, 31, 29-59.	2.7	146
116	The causes of cancer revisited: â€œMitochondrial malignancyâ€•and ROS-induced oncogenic transformation â€" Why mitochondria are targets for cancer therapy. Molecular Aspects of Medicine, 2010, 31, 145-170.	2.7	299
117	Bid integrates intrinsic and extrinsic signaling in apoptosis induced by Î±-tocopheryl succinate in human gastric carcinoma cells. Cancer Letters, 2010, 288, 42-49.	3.2	43
118	MAC'09, Otto and usâ€¦. Mitochondrion, 2010, 10, 583.	1.6	1
119	Suppression of Tumor Growth<i>In vivo</i>by the Mitocan Î±-tocopheryl Succinate Requires Respiratory Complex II. Clinical Cancer Research, 2009, 15, 1593-1600.	3.2	125
120	Liposomal formulation of Î±-tocopheryl maleamide: In vitro and in vivo toxicological profile and anticancer effect against spontaneous breast carcinomas in mice. Toxicology and Applied Pharmacology, 2009, 237, 249-257.	1.3	43
121	Mitochondria as targets for cancer therapy. Molecular Nutrition and Food Research, 2009, 53, 9-28.	1.5	83
122	Vitamin E analogues as mitochondriaâ€targeting compounds: From the bench to the bedside?. Molecular Nutrition and Food Research, 2009, 53, 129-139.	1.5	35
123	Future use of mitocans against tumourâ€initiating cells?. Molecular Nutrition and Food Research, 2009, 53, 147-153.	1.5	7
124	Mitocans, a class of emerging antiâ€cancer drugs. Molecular Nutrition and Food Research, 2009, 53, 7-8.	1.5	81
125	Mitochondria as Targets for Cancer Therapy. , 2009, , 211-249.		1
126	Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches. Current Molecular Pharmacology, 2009, 2, 190-206.	0.7	25

#	Article	IF	Citations
127	Cancer cells with high expression of CD133 exert FLIP upregulation and resistance to TRAILâ€induced apoptosis. BioFactors, 2008, 34, 231-235.	2.6	12
128	Î±-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene, 2008, 27, 4324-4335.	2.6	266
129	CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. Biochemical and Biophysical Research Communications, 2008, 373, 567-571.	1.0	59
130	Daxx inhibits stress-induced apoptosis in cardiac myocytes. Redox Report, 2008, 13, 263-270.	1.4	12
131	Profiling Tumor-Associated Markers for Early Detection of Malignant Mesothelioma: An Epidemiologic Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 163-170.	1.1	53
132	Î±-Lipoic Acid Modulates Extracellular Matrix and Angiogenesis Gene Expression in Non-Healing Wounds Treated with Hyperbaric Oxygen Therapy. Molecular Medicine, 2008, 14, 175-183.	1.9	25
133	Cancer cells with high expression of CD133 exert FLIP upregulation and resistance to TRAIL-induced apoptosis. BioFactors, 2008, 34, 231-5.	2.6	13
134	A Peptide Conjugate of Vitamin E Succinate Targets Breast Cancer Cells with High ErbB2 Expression. Cancer Research, 2007, 67, 3337-3344.	0.4	84
135	Vitamin E Analogs, a Novel Group of â€œMitocans,â€•as Anticancer Agents: The Importance of Being Redox-Silent. Molecular Pharmacology, 2007, 71, 1185-1199.	1.0	131
136	Mitochondria transmit apoptosis signalling in cardiomyocyte-like cells and isolated hearts exposed to experimental ischemia-reperfusion injury. Redox Report, 2007, 12, 148-162.	1.4	76
137	Vitamin E Analogues Inhibit Angiogenesis by Selective Induction of Apoptosis in Proliferating Endothelial Cells: The Role of Oxidative Stress. Cancer Research, 2007, 67, 11906-11913.	0.4	99
138	Apoptosis and inhibition of gap-junctional intercellular communication induced by LA-12, a novel hydrophobic platinum(IV) complex. Archives of Biochemistry and Biophysics, 2007, 462, 54-61.	1.4	22
139	Tumour-initiating cells vs. cancer â€˜stemâ€™ cells and CD133: Whatâ€™s in the name?. Biochemical and Biophysical Research Communications, 2007, 355, 855-859.	1.0	176
140	Î±-Tocopheryl succinate-induced apoptosis in human gastric cancer cells is modulated by ERK1/2 and c-Jun N-terminal kinase in a biphasic manner. Cancer Letters, 2007, 247, 345-352.	3.2	23
141	Vitamin E analogues as a novel group of mitocans: Anti-cancer agents that act by targeting mitochondria. Molecular Aspects of Medicine, 2007, 28, 607-645.	2.7	96
142	Î±â€Tocopheryl succinate inhibits angiogenesis by disrupting paracrine FGF2 signalling. FEBS Letters, 2007, 581, 4611-4615.	1.3	18
143	Vitamin E Analogues and Immune Response in Cancer Treatment. Vitamins and Hormones, 2007, 76, 463-491.	0.7	18
144	Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. Journal of Bioenergetics and Biomembranes, 2007, 39, 65-72.	1.0	116

#	Article	IF	Citations
145	Î±-Tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: Implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Letters, 2006, 580, 1925-1931.	1.3	52
146	Role of thioredoxin-1 in apoptosis induction by Î±-tocopheryl succinate and TNF-related apoptosis-inducing ligand in mesothelioma cells. FEBS Letters, 2006, 580, 2671-2676.	1.3	10
147	Molecular mechanism of â€˜mitocanâ€™-induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins. FEBS Letters, 2006, 580, 5125-5129.	1.3	166
148	Tocopherol-associated protein-1 accelerates apoptosis induced by Î±-tocopheryl succinate in mesothelioma cells. Biochemical and Biophysical Research Communications, 2006, 343, 1113-1117.	1.0	35
149	Expression of human myoglobin in H9c2 cells enhances toxicity to added hydrogen peroxide. Biochemical and Biophysical Research Communications, 2006, 348, 485-493.	1.0	15
150	Î±-Tocopheryl succinate alters cell cycle distribution sensitising human osteosarcoma cells to methotrexate-induced apoptosis. Cancer Letters, 2006, 232, 226-235.	3.2	31
151	Vitamin E analogues as anticancer agents: Lessons from studies with Î±-tocopheryl succinate. Molecular Nutrition and Food Research, 2006, 50, 675-685.	1.5	69
152	Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 327-346.	0.8	86
153	Î±-Tocopheryl succinate selectively induces apoptosis in neuroblastoma cells: potential therapy of malignancies of the nervous system?. Journal of Neurochemistry, 2005, 94, 1448-1456.	2.1	50
154	Vitamin E amides, a new class of vitamin E analogues with enhanced proapoptotic activity. International Journal of Cancer, 2005, 117, 188-193.	2.3	41
155	Oxidative stress in myocardial ischaemia reperfusion injury: a renewed focus on a long-standing area of heart research. Redox Report, 2005, 10, 187-197.	1.4	32
156	Î±-Tocopheryl Succinate Inhibits Malignant Mesothelioma byDisrupting the Fibroblast Growth Factor Autocrine Loop. Journal of Biological Chemistry, 2005, 280, 25369-25376.	1.6	109
157	Vitamin E analogs trigger apoptosis in HER2/erbB2-overexpressing breast cancer cells by signaling via the mitochondrial pathway. Biochemical and Biophysical Research Communications, 2005, 326, 282-289.	1.0	69
158	Hepatic processing determines dual activity of Î±-tocopheryl succinate: a novel paradigm for a shift in biological activity due to pro-vitamin-to-vitamin conversion. Biochemical and Biophysical Research Communications, 2005, 327, 1024-1027.	1.0	28
159	Î±-Tocopheryl succinate induces cytostasis and apoptosis in osteosarcoma cells: the role of E2F1. Biochemical and Biophysical Research Communications, 2005, 331, 1515-1521.	1.0	25
160	Î±-Lipoic acid supplementation inhibits oxidative damage, accelerating chronic wound healing in patients undergoing hyperbaric oxygen therapy. Biochemical and Biophysical Research Communications, 2005, 333, 404-410.	1.0	60
161	Vitamin E Analogs as Anticancer Agents. Nutrition and Disease Prevention, 2005, , .	0.1	0
162	Vitamin E Analogues: A New Class of Inducers of Apoptosis with Selective Anti-Cancer Effects. Current Cancer Drug Targets, 2004, 4, 355-372.	0.8	95

#	Article	IF	Citations
163	Î±-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. British Journal of Cancer, 2004, 90, 1644-1653.	2.9	59
164	Enzymatically modified low-density lipoprotein upregulates CD36 in low-differentiated monocytic cells in a peroxisome proliferator-activated receptor-Î³-dependent way. Biochemical Pharmacology, 2004, 67, 841-854.	2.0	14
165	Aging of Cardiac Myocytes in Culture: Oxidative Stress, Lipofuscin Accumulation, and Mitochondrial Turnover. Annals of the New York Academy of Sciences, 2004, 1019, 70-77.	1.8	126
166	Cyclopentenone prostaglandins induce endothelial cell apoptosis independent of the peroxisome proliferator-activated receptor-Î³. European Journal of Immunology, 2004, 34, 241-250.	1.6	18
167	A vitamin E analogue suppresses malignant mesothelioma in a preclinical model: A future drug against a fatal neoplastic disease?. International Journal of Cancer, 2004, 109, 641-642.	2.3	55
168	Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochemical and Biophysical Research Communications, 2004, 314, 186-191.	1.0	95
169	Î±-Tocopheryl succinate inhibits proliferation of mesothelioma cells by selective down-regulation of fibroblast growth factor receptors. Biochemical and Biophysical Research Communications, 2004, 318, 636-641.	1.0	20
170	Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs. Archives of Biochemistry and Biophysics, 2004, 421, 1-9.	1.4	39
171	Mitochondrial recycling and aging of cardiac myocytes: the role of autophagocytosis. Experimental Gerontology, 2003, 38, 863-876.	1.2	144
172	Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties. Biochemical Pharmacology, 2003, 65, 161-172.	2.0	35
173	Î±-Tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-ÎºB activation. British Journal of Cancer, 2003, 88, 153-158.	2.9	59
174	Vitamin E succinate and cancer treatment: a vitamin E prototype for selective antitumour activity. British Journal of Cancer, 2003, 89, 1822-1826.	2.9	107
175	Mitochondria Play a Central Role in Apoptosis Induced by Î±-Tocopheryl Succinate, an Agent with Antineoplastic Activity:Â Comparison with Receptor-Mediated Pro-Apoptotic Signalingâ€. Biochemistry, 2003, 42, 4277-4291.	1.2	152
176	Vitamin E analogues as inducers of apoptosis: structureâ€"function relation. British Journal of Cancer, 2003, 88, 1948-1955.	2.9	127
177	Î±-Tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability. Biochemical Journal, 2002, 362, 709.	1.7	66
178	Î±-Tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability. Biochemical Journal, 2002, 362, 709-715.	1.7	107
179	The European perspective on vitamin E: current knowledge and future research. American Journal of Clinical Nutrition, 2002, 76, 703-716.	2.2	519
180	Decreased Apoptotic Response of Inclusion-Cell Disease Fibroblasts: A Consequence of Lysosomal Enzyme Missorting?. Experimental Cell Research, 2002, 274, 9-15.	1.2	21

#	Article	IF	Citations
181	Dissociation of Apoptosis Induction and CD36 Upregulation by Enzymatically Modified Low-Density Lipoprotein in Monocytic Cells. Biochemical and Biophysical Research Communications, 2002, 290, 988-993.	1.0	21
182	Î±-Tocopheryl succinate epitomizes a compound with a shift in biological activity due to pro-vitamin-to-vitamin conversion. Biochemical and Biophysical Research Communications, 2002, 293, 1309-1313.	1.0	47
183	Vitamin E analogs: a new class of multiple action agents with anti-neoplastic and anti-atherogenic activity. Apoptosis: an International Journal on Programmed Cell Death, 2002, 7, 179-187.	2.2	32
184	Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clinical Cancer Research, 2002, 8, 863-9.	3.2	144
185	The role of vitamin E in atherogenesis: linking the chemical, biological and clinical aspects of the disease. Atherosclerosis, 2001, 157, 257-283.	0.4	65
186	Coenzyme Q blocks biochemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection. FEBS Letters, 2001, 503, 46-50.	1.3	78
187	Inhibition of Inflammatory Endothelial Responses by a Pathway Involving Caspase Activation and p65 Cleavage. Biochemistry, 2001, 40, 4686-4692.	1.2	70
188	Vitamin E analogues as inducers of apoptosis: implications for their potential antineoplastic role. Redox Report, 2001, 6, 143-151.	1.4	48
189	Lysosomal involvement in apoptosis. Redox Report, 2001, 6, 91-97.	1.4	219
190	Selective cancer cell killing by Î±-tocopheryl succinate. British Journal of Cancer, 2001, 84, 87-89.	2.9	215
191	Induction of cancer cell apoptosis by Î±â€tocopheryl succinate: molecular pathways and structural requirements. FASEB Journal, 2001, 15, 403-415.	0.2	272
192	Î±-Tocopheryl succinate-induced apoptosis in Jurkat T cells involves caspase-3 activation, and both lysosomal and mitochondrial destabilisation. FEBS Letters, 1999, 445, 295-300.	1.3	120
193	alpha-Tocopherol in atherogenesis: do we know its real role?. , 1998, 12, 421-423.		2
194	Secretory Phospholipase A2and Lipoprotein Lipase Enhance 15-Lipoxygenase-Induced Enzymic and Nonenzymic Lipid Peroxidation in Low-Density Lipoproteinsâ€. Biochemistry, 1998, 37, 9203-9210.	1.2	74
195	Radical-induced lipoprotein and plasma lipid oxidation in normal and apolipoprotein E gene knockout (apoEâ€“/â€“) mice: apoEâ€“/â€“ mouse as a model for testing the role of tocopherol-mediated peroxidation in atherogenesis. Journal of Lipid Research, 1998, 39, 354-368.	2.0	31
196	Oxidation of Free Fatty Acids in Low Density Lipoprotein by 15-Lipoxygenase Stimulates Nonenzymic, Î±-Tocopherol-mediated Peroxidation of Cholesteryl Esters. Journal of Biological Chemistry, 1997, 272, 30067-30074.	1.6	62
197	Â-Tocopheryl hydroquinone is an efficient multifunctional inhibitor of radical-initiated oxidation of low density lipoprotein lipids. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 7885-7890.	3.3	82
198	Inhibition of LDL oxidation by ubiquinol-10. A protective mechanism for coenzyme Q in atherogenesis?. Molecular Aspects of Medicine, 1997, 18, 85-103.	2.7	47

#	Article	IF	Citations
199	Requirement for, Promotion, or Inhibition by Î±-Tocopherol of Radical-Induced Initiation of Plasma Lipoprotein Lipid Peroxidation. Free Radical Biology and Medicine, 1997, 22, 57-71.	1.3	241
200	Oxidation of parenteral lipid emulsion by ambient and phototherapy lights: Potential toxicity of routine parenteral feeding. Journal of Pediatrics, 1995, 126, 785-790.	0.9	152
201	Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Letters, 1993, 331, 281-284.	1.3	151
202	Cooperative effect of fructose bisphosphate and glyceraldehyde-3-phosphate dehydrogenase on aldolase action. BBA - Proteins and Proteomics, 1990, 1037, 307-312.	2.1	21
203	A further characterization of alanine dehydrogenase fromStreptomyces aureofaciens. Journal of Basic Microbiology, 1989, 29, 185-189.	1.8	14
204	A direct-injection reversed-phase liquid chromatographic micromethod for studying the kinetics of terminal reactions of tetracycline biosynthesis. Analytical Biochemistry, 1989, 181, 125-129.	1.1	9
205	Purification and partial characterization of alanine dehydrogenase from Streptomyces aureofaciens. Archives of Microbiology, 1988, 150, 438-440.	1.0	28
206	Enzymic degradation of bromoxynil by cell-free extracts ofStreptomyces felleus. Folia Microbiologica, 1988, 33, 349-354.	1.1	6
207	High-Performance Liquid Chromatography of Derivatives Involved in the Terminal Steps of Tetracycline Biosynthesis inStreptomyces Aureofaciens. Journal of Liquid Chromatography and Related Technologies, 1988, 11, 2789-2800.	0.9	2
208	Partial purification and characterization of anhydrotetracycline oxygenase ofStreptomyces aureofaciens. Journal of Basic Microbiology, 1987, 27, 529-533.	1.8	12
209	Enzymes of secondary metabolism and the biosynthesis of macrolide antibiotics. Folia Microbiologica, 1986, 31, 402-421.	1.1	11
210	Effect of tetracycline derivatives and some cations on the activity of anhydrotetracycline oxygenase. Biotechnology Letters, 1983, 5, 537-542.	1.1	16